Sodium-Glucose Cotransporter-2 Inhibitors and Prevention of Adverse Kidney Outcomes in Type 2 Diabetes: A Clinical Multiethnic Asian Cohort.

ABSTRACT:

Rationale & objective

Studies of sodium-glucose cotransporter-2 (SGLT2) inhibitors assessing kidney outcomes among Asians with type 2 diabetes in a clinical setting are limited. We assessed the association of SGLT2 inhibitors with kidney and safety outcomes in a diverse multiethnic Asian population with type 2 diabetes in a clinical setting.

Study design

Retrospective cohort study.

Setting & participants

Patients with type 2 diabetes from multi-institutional SingHealth Diabetes Registry in Singapore.

Exposure

Initiators of SGLT2 inhibitors between 2014 to 2018 with a median follow-up duration of 25.6 months (interquartile range, 17.9-31.4).

Outcomes

Composite kidney outcome (≥40% estimated glomerular filtration rate [eGFR] decline or incident kidney fail

SUBMITTER: Feng L 

PROVIDER: S-EPMC11907467 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature